Poxel S.A. (0RA2.L)

1.6000 0.0000 (0.00%) As of 08:29AM BST. Market open.

Poxel S.A.

Immeuble Le Sunway
259-261 Avenue Jean JaurEs
Lyon 69007
France
33 4 37 37 20 10
https://www.poxelpharma.com

Sector(s): 
Industry: 
Full-time employees: 15

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Thomas Kuhn M.B.A., Pharm D MBA, Pharm.D.	Co-Founder, CEO & Director	412.64k	N/A	N/A
Dr. Sébastien Bolze Ph.D., Pharm D Ph.D., Pharm.D.	Co-Founder, COO and Executive VP of Project Management, Non Clinical & Manufacturing Operations	N/A	N/A	N/A
Dr. Pascale Fouqueray-Grellier M.D., Ph.D.	Co-Founder and Executive VP of Clinical Development & Regulatory Affairs	N/A	N/A	N/A
Dr. Sophie Hallakou-Bozec Ph.D.	Co-Founder and Executive VP of R&D Pharmacology & Scientific Communication	N/A	N/A	N/A
Arthur Rouille	Investor Relations Officer	N/A	N/A	N/A
Mr. Quentin Durand	Executive VP, Chief Legal Officer & Head of Corporate Social Responsibility	N/A	N/A	N/A
Ms. Sylvie Bertrand	Vice President of Human Resources	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.

Corporate governance

Poxel S.A.’s ISS governance QualityScore as of 1 April 2024 is 10. The pillar scores are Audit: 5; Board: 9; Shareholder rights: 4; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.